|
Hello fellow investors / traders,
Our biotech play yesterday delivered solid 18% gains and close near highs, today we focus on another biotech play making big waves.
Check out PharmaCyte Biotech Inc (PMCB) now.
PMCB is a highly liquid trader that has pulled back significantly over the past few months.
Yesterday however, PMCB saw a strong uptick as it found support at $0.10 last week.
We think there could be strong continuation of
this bounce as it potentially heads to its 100 day moving average of
around $0.20.
You guessed it, that's 50% short term gain potential right here.
Of course we think the long term potential is so
much greater, but as investors and traders we must focus on the short
and long term.
PMCB
is a clinical stage biotechnology company developing targeted
treatments for cancer and diabetes using its signature live cell
encapsulation technology Cell-in-a-Box®.
PMCB's Cell-in-a-Box® is a way to enclose living cells in
protective "cocoons" about the size of the head of a pin - These
capsules are placed as close to the cancerous tumor as possible to
enable the delivery of the highest levels of the cancer-killing drug at
the source of the cancer. This "targeted chemotherapy" has proven
remarkably effective in past clinical trials.
Reasons we're excited about this stock:
-
This technology shows great promise. As a matter of fact,
in the first round of testing patients received two courses of
ifosfamide at one-third the regular dose plus a urological protectant
after transplantation of 300 capsules. Median survival after diagnosis
rose to 40 weeks, compared with historical control of 28 weeks with
gemcitabine, and 1-year survival increased to 36%, compared with 18% for
gemcitabine.
-
The European Medicines Agency
(The European version of the FDA) has fast-tracked this treatment in
order to cut the time it takes to get to market. That is obviously a
great thing for patients and investors.
-
PMCB's cell- in-a-box technology was named a Near Term Approch in the The Journal of the National Cancer Institute.
The JNCI was established in 1940 and is internationally acclaimed as
the source for the most up-to-date news and information from the rapidly
changing fields of cancer research and treatment. Coverage in the
Journal of the National Cancer Institute brings the kind of credibility
that investors like to see when making long term bets on microcap
companies.
This is why we're excited to bring you a company in phase 2b of clinical trials for treating the terrible disease.
So while their current clinical trials are centered around
the ability to treat pancreatic cancer, there is potential for this
technology to treat several forms of cancer.
Biotechs can yield some of the largest returns out of any
other industry in the microcap space, so when we find one with a story
like this, we get pretty excited.
Make sure you're ready to book your profits with PMCB! - See more at: http://whisperfromwallstreet.com/clinical-stage-biotech-gets-fast-tracked-pmcb/#sthash.okL1L2zW.dpuf
PMCB is a clinical stage biotechnology company developing targeted
treatments for cancer and diabetes using its signature live cell encapsulation
technology Cell-in-a-Box®.
PMCB's Cell-in-a-Box® is a way to enclose living cells in protective
"cocoons" about the size of the head of a pin - These capsules are placed
as close to the cancerous tumor as possible to enable the delivery of the
highest levels of the cancer-killing drug at the source of the cancer. This
"targeted chemotherapy" has proven remarkably effective in past clinical
trials.
Reasons we're excited about PMCB
1. This
technology shows great promise. As a matter of fact, in the first round of
testing patients received two courses of ifosfamide at one-third the regular
dose plus a urological protectant after transplantation of 300 capsules. Median
survival after diagnosis rose to 40 weeks, compared with historical control of
28 weeks with gemcitabine, and 1-year survival increased to 36%, compared with
18% for gemcitabine.
2. TheEuropean Medicines Agency (The European
version of the FDA) has fast-tracked this treatment in order to cut the time it
takes to get to market. That is obviously a great thing for patients and
investors.
3. PMCB's
cell- in-a-box technology was named a Near Term Approach in the The Journal of the
National Cancer Institute. The JNCI was established in 1940 and is
internationally acclaimed as the source for the most up-to-date news and
information from the rapidly changing fields of cancer research and treatment.
Coverage in the Journal of the National Cancer Institute brings the kind of
credibility that investors like to see when making long term bets on microcap
companies.
We are excited to bring you a company in phase 2b of clinical
trials for treating the terrible disease.
So while their current clinical trials are centered around the ability to
treat pancreatic cancer, there is potential for this technology to treat
several forms of cancer.
Recent News
As
we saw yesterday, and over the past couple of months, biotechs are on
fire and can yield some of the largest returns in the market, so when we
find one with a story like this, we get pretty
excited.
Continue your research now and make sure you're ready to bank with PMCB.
www.ShiznitStocks.com
Disclaimer
Never invest in any stock featured on our
site or emails unless you can afford to lose your entire investment. For full
disclaimer click here.
ShiznitStocks.com employees are not registered as an Investment Adviser in any
jurisdiction whatsoever. The disclaimer is to be read and fully understood
before using our site, or joining our email list. None of the materials or
advertisements herein constitute offers or solicitations to purchase or sell
securities of the companies profiled herein and any decision to invest in any
such company or other financial decisions should not be made based upon the
information provide herein. Instead ShiznitStocks.com strongly urges you
conduct a complete and independent investigation of the respective companies
and consideration of all pertinent risks. ShiznitStocks.com does not offer such
advice or analysis, and ShiznitStocks.com further urges you to consult your own
independent tax, business, financial and investment advisors. Investing in
micro-cap and growth securities is highly speculative and carries and extremely
high degree of risk. It is possible that an investor's investment may be lost
or impaired due to the speculative nature of the companies profiled. Any
statements that express or involve discussions with respect to predictions,
expectations, beliefs, plans, projections, objectives, goals, assumptions or
future events or performance are not statements of historical fact may be
"forward looking statements". Forward looking statements are based on
expectations, estimates, and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through use of
words such as "projects", "foresee", "expects",
"will", "anticipates", "estimates",
"believes", "understands", or that by statements indicating
certain actions "may", "could", or "might" occur.
Understand there is no guarantee past performance will be indicative of future
results. In preparing this publication, ShiznitStocks.com has relied upon
information supplied by its customers, and press releases which it believes to
be reliable; however, such reliability cannot be guaranteed. Investors should
not rely on the information contained in this website. Rather, investors should
use the information contained in this website as a starting point for doing
additional independent research on the featured companies. The advertisements
in this website are believed to be reliable, however, ShiznitStocks.com and its
owners, affiliates, subsidiaries, officers, directors, representatives and
agents have not completed any due diligence or research on the companies advertised
herein and disclaim any liability as to the completeness or accuracy of the
information contained in any advertisement and for any omissions of materials
facts from such advertisement. ShiznitStocks.com is not responsible for any
claims made by the companies advertised herein. ShiznitStocks.com may receive
compensation and its employees and affiliates may own stock that they have
purchased in the open market either prior, during, or after the release of the
companies profile which is an inherent conflict of interest in
ShiznitStocks.com statements and opinions and such statements and opinions
cannot be considered independent. ShiznitStocks.com reserves the right to buy
and sell shares of the profiled company on the open market before, during or
after the release of the company profile. In such an event, ShiznitStocks.com
will not update its disclaimer to reflect any shares bought or sold on the open
market during the profile coverage. ShiznitStocks.com and its management may
benefit from any increase in the share price of the profiled companies and hold
the right to sell the shares bought at any given time including shortly after
the release of the companies profile. ShiznitStocks.com has
been compensated two thousand dollars via electronic transfer from a non-affiliated third party for the
profile of PMCB. ShiznitStocks.com may on occasion accept compensation in
restricted or free-trading shares for it's marketing services of the company
being profiled, and the third party that might have compensated ShiznitStocks.com
may hold free-trading shares of the company being profiled and could very well
be selling shares of the companies stock at the same time the profile is being
disseminated to potential investors; this should be viewed as a definite
conflict of interest and as such, the reader should take this into
consideration. If ShiznitStocks.com ever accepts compensation in the form
of restricted or free trading shares of the company being profiled and decides
to sell these shares into the public market at any time before, during, or
after the release of the companies profile our disclaimer will be updated
accordingly reflecting the current position of those free trading shares
received as compensation for our services. |